Advertisement

Topics

Latest "ConSynance Therapeutics, Inc." News Stories

03:41 EST 18th January 2019 | BioPortfolio

Here are the most relevant search results for "ConSynance Therapeutics, Inc." found in our extensive news archives from over 250 global news sources.

More Information about ConSynance Therapeutics, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ConSynance Therapeutics, Inc. for you to read. Along with our medical data and news we also list ConSynance Therapeutics, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of ConSynance Therapeutics, Inc. Companies for you to search.

Showing "ConSynance Therapeutics" News Articles 1–25 of 8,300+

Thursday 17th January 2019

Agoraphobia Global Clinical Trials Review, H2, 2018 [Report Updated: 25102018] Prices from USD $2500

Agoraphobia Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Agoraphobia Global Clinical Trials Review, H2, 2018" provides an overview of Agoraphobia clinical trials scenario. This report provides top line data relating to the clinical trials on Agoraphobia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across ...


Urticaria Pigmentosa Mastocytosis, Mastocytoma Global Clinical Trials Review, H2, 2018 [Report Updated: 28092018] Prices from USD $2500

Urticaria Pigmentosa Mastocytosis, Mastocytoma Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Urticaria Pigmentosa Mastocytosis, Mastocytoma Global Clinical Trials Review, H2, 2018" provides an overview of Urticaria Pigmentosa Mastocytosis, Mastocytoma clinical trials scenario. This report provides top line data relating to the clinical trials on Urticaria Pigmen...

LISTEN: FDA furloughs, ’80s pop radio, and video game therapeutics

Is the FDA going broke? Can video games be drugs? And when did "Flashdance" come out? Find out on this week's episode of "The Readout LOUD" #podcast.


Zymeworks Reports Second Investigational New Drug (IND)-Submission Milestone Achieved in Lilly Collaboration

Lilly’s second immune-oncology candidate using Zymeworks’ novel Azymetric™ platform to start clinical trials Zymeworks to receive milestone payment of US$8.0 million for this second IND submission Lilly is one of eight pharma partners; INDs by others anticipated Total value of remaining potent...

FDA’s Gottlieb Adds Confusion to Aimmune’s Claims of Shutdown Delay

The first biotech company to cite the partial government shutdown as a reason for serious delay was Aimmune Therapeutics (NASDAQ: AIMT), as Xconomy reported Tuesday. The announcement, however, soon raised more questions than answers. Aimmune reported in a regulatory filing Tuesday that the FDA would not start reviewing its peanut-allergy treatment, AR101, because of the […]

Millendo Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Millendo Therapeutics, Inc. (“Millendo” or the “Company”) (NASDAQ: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that on January 15, 2019, the Compensation Committee of the Board of Directors approved, effect

Alnylam nets $382.3mm via FOPO

Alnylam Pharmaceuticals Inc. netted $382.3mm through the follow-on public offering of 5mm common shares at $77.50 each. The c...

Boehringer and Bioharmony partner to develop therapies for bacterial infections

Bioharmony Therapeutics Inc. and Boehringer Ingelheim GMBH agreed to collaborate on the development of bacteriophage lysins f...

Upsized public offering nets $75.2mm for Stemline

Stemline Therapeutics Inc. (oncology) netted $75.2mm through an upsized public sale of 8.89mm common shares at $9. Funds will...

Revance FOPO nets $94mm

Revance Therapeutics Inc. netted $94mm through the public offering of 5.9mm shares at $17. The company will use the proceeds ...

Vitruvius Therapeutics gets FDA nod for vitamin B-12 injection

Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today that a poster entitled “Phase 1 Results from the Phase 1/3 FIGHT Study Evaluating Bemarituzumab and mFOLFOX6 in Advanced Gastric/GEJ Ca

Adrenal Insufficiency Global Clinical Trials Review, H2, 2018 [Report Updated: 25102018] Prices from USD $2500

Adrenal Insufficiency Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Adrenal Insufficiency Global Clinical Trials Review, H2, 2018" provides an overview of Adrenal Insufficiency clinical trials scenario. This report provides top line data relating to the clinical trials on Adrenal Insufficiency. Report includes an overview of trial numbers and their average enrol...

Allergic Conjunctivitis Global Clinical Trials Review, H2, 2018 [Report Updated: 25102018] Prices from USD $2500

Allergic Conjunctivitis Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Allergic Conjunctivitis Global Clinical Trials Review, H2, 2018" provides an overview of Allergic Conjunctivitis clinical trials scenario. This report provides top line data relating to the clinical trials on Allergic Conjunctivitis. Report includes an overview of trial numbers and their avera...

Precision Therapeutics’ stock soars after its Skyline Medical division expands footprint in New England

The company sold six STREAMWAY systems to Yale University’s ambulatory outpatient surgical center

$MRKR to Present at the Phacilitate Leaders World & World Stem Cell Summit 2019 January 23 https://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-the-phacilitate-leaders-world--world-stem-cell-summit-2019-300779802.html …

$MRKR to Present at the Phacilitate Leaders World & World Stem Cell Summit 2019 January 23 https://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-the-phacilitate-leaders-world--world-stem-cell-summit-2019-300779802.html …

Abscess Global Clinical Trials Review, H2, 2018 [Report Updated: 25102018] Prices from USD $2500

Abscess Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Abscess Global Clinical Trials Review, H2, 2018" provides an overview of Abscess clinical trials scenario. This report provides top line data relating to the clinical trials on Abscess. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The r...

Ablexis Announces Expansion of Non-Exclusive Perpetual License Agreement with Eli Lilly and Company

Expanded rights enable broader use of AlivaMab Mouse™ platform Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse platform technology for antibody drug discovery, today announced the expansion of its existing non-exclusive perpetual license agreement

LifeMap Sciences to Present Novel WGS Structural Variation Interpretation at PMWC 2019

LifeMap Sciences, a subsidiary of AgeX Therapeutics, Inc., announced today that it will be presenting its novel whole genome sequencing (WGS) interpretation solutions at Precision Medicine World Conference 2019 in Silicon Valley, on January 22nd, as part of the Clinical and Research Tools Showcase. The presentation will discuss the challenges face...

Switching Between Reference and Biosimilar Infliximab

Is switching between infliximab and its biosimilar safe and efficacious in patients with inflammatory disorders? Alimentary Pharmacology & Therapeutics

Revance Announces Pricing of Public Offering of Common Stock

Revance Therapeutics, Inc. (Nasdaq:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced the pricing of an underwritten public offering of 5,882,353 shares of its common stock at a price to the public of $17.00 per share. Revance ...

Hardman & Co Research: Allergy Therapeutics (AGY): Trading update: gaining market share

Hardman & Co Research 17-Jan-2019 / 09:56 GMT/BST Hardman & Co: Trading update: gaining market share AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. The Pollinex Quattro (PQ) platform, the ultra-short course subcutaneous allergy immunotherapy (AIT), continues to gain market share, despite its availability in the EU only on a 'named-patien...

FDA Panel Nod For Osteoporosis Drug, PTIE Gets Research Funding, ALDR On Watch

Today's Daily Dose brings you news about Alder Biopharma's after-hours stock movement; Mirati's stock offering; FDA panel recommendation of Amgen/UCB's osteoporosis drug Evenity; and Pain Therapeutics' grant award.

Wednesday 16th January 2019

Aortic Valve Stenosis Global Clinical Trials Review, H2, 2018 [Report Updated: 31102018] Prices from USD $2500

Aortic Valve Stenosis Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Aortic Valve Stenosis Global Clinical Trials Review, H2, 2018" provides an overview of Aortic Valve Stenosis clinical trials scenario. This report provides top line data relating to the clinical trials on Aortic Valve Stenosis. Report includes an overview of trial numbers and their average enrol...

Mirati Therapeutics doses first patient in MRTX849 trial

Mirati Therapeutics has dosed the first patient in a Phase I/II clinical trial evaluating MRTX849 as a single agent for...Read More... The post Mirati Therapeutics doses first patient in MRTX849 trial appeared first on Drug Development Technology.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks